Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3

Methodology|Interests|Funding|Corrections

Monograph series

Combinations and unimolecular co-agonists

Fixed-ratio co-formulations and single molecules engineered to engage more than one satiety system.

All series Incretin receptor agonists Amylin analogues Combinations and unimolecular co-agonists Growth-hormone axis Repair and regeneration Neuroactive peptides Immune modulators Mitochondrial and metabolic cofactors Melanocortin receptor agonists Reproductive-axis peptides

Monographs in this series

2 documents

Amycretin

CEI-MN-017Combinations and unimolecular co-agonistsPhase 21 assessed outcomeversion 2.0

A single peptide engineered to activate both the amylin and GLP-1 receptor systems, combining two complementary satiation mechanisms without the pharmaceutical complexity of a fixed-ratio co-formulation.

Low11 Aug 2024
CagriSema (cagrilintide with semaglutide)

CEI-MN-006Combinations and unimolecular co-agonistsPhase 32 assessed outcomesversion 4.1

The combination pairs two complementary satiation mechanisms: GLP-1 receptor agonism acting on hypothalamic and hindbrain appetite circuits, and amylin receptor agonism acting principally at the area postrema to promote meal…

Moderate24 Feb 2025

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.